Non-Small Cell Lung Cancer (NSCLC)

Latest News

Phase 3 CROWN trial findings suggest that patients with ALK-positive NSCLC may maintain efficacy even after reducing lorlatinib dosing to mitigate AEs.

Elucidating Lorlatinib Benefit, ALK TKI Sequencing in ALK-Positive NSCLC

April 14th 2025

Phase 3 CROWN trial findings suggest that patients with ALK-positive NSCLC may maintain efficacy even after reducing lorlatinib dosing to mitigate AEs.

Disease-free survival and minimal residual disease event-free status was maintained for most patients with adjuvant osimertinib for EGFR-mutant NSCLC.

Plasma-Based MRD Analysis May Predict Recurrence in EGFR-Mutant NSCLC

By Roman Fabbricatore

April 12th 2025

Patients with ALK-positive NSCLC not vulnerable to neurological adverse effects or prone to weight issues, might benefit from treatment with lorlatinib.

Considerations for TKI Selection and Sequencing in ALK-Positive NSCLC

By Roman Fabbricatore

April 7th 2025

Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.

EU’s CHMP Recommends Approving Perioperative Nivolumab Combo in NSCLC

By Russ Conroy

April 2nd 2025

The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.

Osimertinib Shows Sustained Survival Benefit in EGFR-Mutant NSCLC

By Roman Fabbricatore

March 30th 2025

Latest CME Events & Activities

Go To PER in Chicago

May 30, 2025 - June 3, 2025

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

26th Annual International Lung Cancer Congress®

July 25-26, 2025

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies